CN107050005A - A kind of pharmaceutical composition for treating atherosclerosis and its application - Google Patents
A kind of pharmaceutical composition for treating atherosclerosis and its application Download PDFInfo
- Publication number
- CN107050005A CN107050005A CN201710073121.2A CN201710073121A CN107050005A CN 107050005 A CN107050005 A CN 107050005A CN 201710073121 A CN201710073121 A CN 201710073121A CN 107050005 A CN107050005 A CN 107050005A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- eugenol
- rubiadin
- atherosclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to a kind of pharmaceutical composition for treating atherosclerosis and its application；The pharmaceutical composition is formulated comprising following raw materials according：Rubiadin, eugenol, Ethyl vanillin；Suppress the rise of Induced by High Fat Diet in Rats blood fat with obvious, can effectively treat atherosclerosis and effect is obvious, the stable advantage suitable for patient's long-term taking of Quality Control.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to a kind of pharmaceutical composition for treating atherosclerosis and its should
With.
Background technology
Atherosclerosis is one kind of artery sclerosis, takes place mostly in big or middle endarterium, and occur containing cholesterol,
The yellow atheromatous plaque material of class fat etc., is caused by fat metabolic disturbance, neural blood vessel functional disturbance more.Often result in thrombus shape
Into, blood supply disorder etc..The morbidity crowd of atherosclerosis is more common in the male of more than 40 years old and the women after climacteric.This disease
It is often accompanied by hypertension, hypercholesterolemia or diabetes etc..Atherosclerosis is a kind of common disease, frequently-occurring disease, the death rate and
One of higher disease of disability rate, seriously endangers the life and health of the mankind, is common in brain worker, is also that the elderly causes
The one of the main reasons died of illness.
At present, not yet there is the medicine that preferably treatment atherosclerosis occurs and developed.Common prevention is rationally to drink
Eat, take exercises, take a good rest based on, but effect is undesirable.
The content of the invention
It is an object of the invention to overcome defect of the prior art stable there is provided a special quality control, safely and effectively, natural nothing
Poison and a kind of pharmaceutical composition for treating atherosclerosis suitable for long-term taking and its application.
The object of the present invention is achieved like this：The pharmaceutical composition is formulated comprising following raw materials according：The different madder of methyl
Element, eugenol, Ethyl vanillin.
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：1-100 parts of Rubiadin, 8-100 parts of eugenol, 10-100 parts of Ethyl vanillin.
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：1-80 parts of Rubiadin, 8-80 parts of eugenol, 10-80 parts of Ethyl vanillin.
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：1-150 parts of Rubiadin, 8-50 parts of eugenol, 10-50 parts of Ethyl vanillin.
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：1 part of Rubiadin, 8 parts of eugenol, 15 parts of Ethyl vanillin.
The invention provides application of the aforementioned pharmaceutical compositions in the medicine for preparing treatment atherosclerosis.
Rubiadin of the present invention, eugenol, Ethyl vanillin can be directly by being commercially available, can also
Obtained by plant extract.The present invention pulverizes and sieves above-mentioned raw materials respectively by weight, mixes, and loads capsule or is compressed to
Tablet；Or mixed with pharmaceutically acceptable carrier or diluent, it is reloaded into capsule or is compressed to tablet.
Present invention also offers the instructions of taking of described pharmaceutical composition, its dose is in terms of said composition：Adult, 6~
8mg/ times, 3 times/day, you can reach the effect for the treatment of atherosclerosis clinical symptoms, particularly point out, the special population such as pregnant woman
It need to be followed the doctor's advice when taking, its special adverse reaction is not yet found at present.Treatment of the present invention means the treatment after morbidity, no
Represent the intervention of premorbid.
Heretofore described Rubiadin, molecular formula is C15H10O4, molecular weight is 254.24, molecular structural formula
For：
Eugenol, molecular formula is C5H8O, molecular weight is 84.12.Molecular structural formula is：
Ethyl vanillin, molecular formula is C9H10O3, molecular weight is 166.18.Molecular structural formula is：
Find according to the study, it is athero- that the composition that Rubiadin, eugenol, Ethyl vanillin are constituted can treat artery
Hardening model rat blood serum cholesterol, triglycerides, low-density lipoprotein rise, treat atherosclerosis model rats artery
Patch is formed, and treats atherosclerosis model rats Artery injury, treats atherosclerosis model rats intra-arterial
Chrotoplast is damaged.
The present invention to rat blood serum cholesterol, triglycerides, low-density lipoprotein assay by having found that artery is athero-
Hardening model rat blood serum cholesterol, triglycerides, low-density lipoprotein content are significantly raised, and pharmaceutical composition of the invention can
Effectively to treat atherosclerosis model rats serum cholesterol, triglycerides, the rise of low-density lipoprotein content.
The present invention is by visually observing discovery to rat chest aorta, and atherosclerosis model rats artery plaque is bright
Aobvious, pharmaceutical composition of the invention can effectively treat atherosclerotic rat artery plaque and be formed.
The present invention to rat chest aorta om observation by having found, atherosclerosis model rats Artery injury
Substantially, pharmaceutical composition of the invention can effectively treat atherosclerotic rat Artery injury.
Heretofore described Rubiadin, eugenol, Ethyl vanillin both from natural drug extract component,
Compared with traditional Chinese medicine, have the advantages that quality controllable.Found by zoopery and clinical patients are on probation, the present invention has
Substantially suppress the rise of Induced by High Fat Diet in Rats blood fat, can effectively treat atherosclerosis and effect substantially, with Quality Control it is stable and
Advantage suitable for patient's long-term taking.
Brief description of the drawings
Fig. 1 is that pharmaceutical composition of the present invention to atherosclerosis model rats aorta pectoralis morphology influence figure, (see by naked eyes
Examine).
Fig. 2 is pharmaceutical composition of the present invention to atherosclerosis model rats aorta pectoralis morphology influence figure (light microscopic 400
×)。
Embodiment
The present invention is a kind of pharmaceutical composition for treating atherosclerosis and its application, and the pharmaceutical composition is comprising following
Raw material is formulated：Rubiadin, eugenol, Ethyl vanillin.
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：1-100 parts of Rubiadin, 8-100 parts of eugenol, 10-100 parts of Ethyl vanillin.
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：1-80 parts of Rubiadin, 8-80 parts of eugenol, 10-80 parts of Ethyl vanillin.
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：1-50 parts of Rubiadin, 8-50 parts of eugenol, 10-50 parts of Ethyl vanillin.
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：1 part of Rubiadin, 8 parts of eugenol, 15 parts of Ethyl vanillin.
The invention provides application of the aforementioned pharmaceutical compositions in the medicine for preparing treatment atherosclerosis.
In order to more clearly explain the present invention, it is further described in conjunction with specific embodiment.It is specific real
Under applying for example：
Embodiment one
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：0.8 part of Rubiadin, 7 parts of eugenol, 101 parts of Ethyl vanillin.
Embodiment two
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：102 parts of Rubiadin, 7.5 parts of eugenol, 9 parts of Ethyl vanillin.
Embodiment three
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：101 parts of Rubiadin, 102 parts of eugenol, 8 parts of Ethyl vanillin.
Example IV
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：1 part of Rubiadin, 8 parts of eugenol, 10 parts of Ethyl vanillin.
Embodiment five
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：100 parts of Rubiadin, 100 parts of eugenol, 100 parts of Ethyl vanillin.
Embodiment six
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：50.5 parts of Rubiadin, 54 parts of eugenol, 55 parts of Ethyl vanillin.
Embodiment seven
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：80 parts of Rubiadin, 44 parts of eugenol, 80 parts of Ethyl vanillin.
Embodiment eight
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：40.5 parts of Rubiadin, 80 parts of eugenol, 45 parts of Ethyl vanillin.
Embodiment nine
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：25.5 parts of Rubiadin, 50 parts of eugenol, 50 parts of Ethyl vanillin.
Embodiment ten
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：50 parts of Rubiadin, 29 parts of eugenol, 30 parts of Ethyl vanillin.
Embodiment 11
A kind of pharmaceutical composition for treating atherosclerosis, the pharmaceutical composition is comprising following raw materials according according to parts by weight
It is formulated：1 part of Rubiadin, 8 parts of eugenol, 15 parts of Ethyl vanillin.
Above-described embodiment is only intended to clearly illustrate example of the present invention, and the not restriction to embodiment.
For the general technical staff of art, other various forms of changes can also be made on the basis of the above description
Or change.There is no necessity and possibility to exhaust all the enbodiments, and the obvious change thus amplified out
Or among changing still in the invention scope of the claims.
The present invention can by being prepared into various various forms of medicaments to Rubiadin, eugenol, Ethyl vanillin,
Such as：The forms such as aqueous solvent, powder and mixture；When needing to prepare aqueous solvent medicine, the different madder of methyl are weighed according to following weight
Plain 1mg, eugenol 8mg, Ethyl vanillin 15mg, mix, are dissolved in tri-distilled water, packing.When needing to prepare powder according to
Following weight weighs medicine, Rubiadin 0.1g, eugenol 0.8g, Ethyl vanillin 15g, mixing, packing.When need
When preparing mixture medicine is weighed according to following deal, Rubiadin 0.1g, eugenol 0.8g, Ethyl vanillin 0.15g,
Mixing, packing, filling capsule.
Test example：The detection present invention is to atherosclerosis model rats serum cholesterol, triglycerides, low-density lipoprotein
Bai Hanliang, aorta pectoralis naked eyes form, morphology.
1st, medicine：Rubiadin, eugenol, Ethyl vanillin, Lovastatin are limited from Beijing cloud scientific research science and technology
Company purchases.
2nd, animal：Sprague-Dawley (SD) rat, 6 week old, male, 180~220g, cleaning grade are real by Henan Province
Animal center offer is provided.
3rd, experiment packet：Rat adapts to raise 1 week in laboratory, without exception in activity, feed, excrement, 40 rats
4 groups are randomly divided into by table of random number：(1) Normal group；(2) Atherosclerosis Model group；(3) Lovastatin group
(100mg/kg)；(4) of the present invention group (5mg/kg).
4th, experiment content：Rat blood serum cholesterol, triglycerides, low-density lipoprotein Content, aorta pectoralis naked eyes
Form, morphology.
5th, statistical method：All data are with mean ± standard deviationRepresent.Group difference compare with ANOVA and
Newman-Student Multiple range tests；T check analyses, are completed by the statistical softwares of SPSS 13.0, and bilateral P ＜ 0.05 think difference
There is conspicuousness.
6th, result
6.1 present invention are to atherosclerosis model rats serum cholesterol, triglycerides, low-density lipoprotein content
Influence：Result of the test shows, Atherosclerosis Model group rat blood serum cholesterol, triglycerides, low-density lipoprotein content
It is significantly higher than Normal group (P ＜ 0.05), present invention group rat blood serum cholesterol, triglycerides, low-density lipoprotein content
It is substantially less than Atherosclerosis Model group (P ＜ 0.05).(the results are shown in Table 1)
Influence of the present invention of table 1 to atherosclerosis model rats blood fat
Note：* P ＜ 0.05, the #P ＜ 0.05 compared with Lovastatin group compared with Atherosclerosis Model group.
6.2 as shown in figure 1, for pharmaceutical composition of the present invention to atherosclerosis model rats aorta pectoralis morphology influence
Scheme (visually observing).As can be seen from the figure atherosclerosis model rats artery plaque is obvious, drug regimen of the invention
Thing can effectively treat atherosclerotic rat artery plaque and be formed.Normal group shown in Fig. 1 is 1；Artery is athero-
Hardening model group is 2；Lovastatin group is 3；Present invention group is 4.
6.3 as shown in Fig. 2 for pharmaceutical composition of the present invention to atherosclerosis model rats aorta pectoralis morphology influence
Scheme (light microscopic 400 ×).It can be seen that atherosclerosis model rats Artery injury is substantially, medicine of the invention
Compositions can effectively treat atherosclerotic rat Artery injury.Normal group shown in Fig. 2 is 1；It is dynamic
Pulse atherosclerosis model group is 2；Lovastatin group is 3；Present invention group is 4.
Pharmaceutically acceptable carrier of the present invention or the form and feature of diluent are by by mixed activity
Amount, method of administration, physiological disposition (including absorb, be distributed, be metabolized, drain) and the other known variable of composition are determined.
Necessarily " acceptable ", i.e., they should can be adapted to these carriers with other compositions of preparation, not interfere with the effect of said preparation
And it is not detrimental to the recipient of said preparation.For example, used pharmaceutical carriers can be solid or liquid.Solid carrier
Example be lactose, carclazyte, sucrose, talcum powder, gelatin, agar, pectin, gum arabic, magnesium stearate, stearic acid, poly- second
Glycol, polyvinylpyrrolidone, collagen hydrolysate etc..The example of liquid-carrier is phosphate buffered saline solution, syrup, breast
Liquid, wetting agent, sterile solution etc..Similarly, carrier or diluent may include time delay material well known in the art, such as individually
Glycerin monostearate or distearin or the mixture with wax.Large-scale medicament forms can be used.Therefore, such as
Fruit uses solid carrier, and said preparation can be placed on hard gelatine capsule, into lozenge or lozenge with piece agent, with powder or particle form
Form.The change of the amount of solid carrier will be very big, but preferably about 50mg to about 1g.When using liquid-carrier, preparation can
With into the form of syrup, emulsion, soft gelatine capsule.
Claims (6)
1. a kind of pharmaceutical composition for treating atherosclerosis, it is characterised in that：The pharmaceutical composition is matched somebody with somebody comprising following raw materials according
System is formed：Rubiadin, eugenol, Ethyl vanillin.
2. a kind of pharmaceutical composition for treating atherosclerosis according to claim 1, it is characterised in that：The medicine group
Compound is formulated comprising following raw materials according according to parts by weight：1-100 parts of Rubiadin, 8-100 parts of eugenol, ethyl are fragrant
Blue 10-100 parts of element.
3. a kind of pharmaceutical composition for treating atherosclerosis according to claim 1, it is characterised in that：The medicine group
Compound is formulated comprising following raw materials according according to parts by weight：1-80 parts of Rubiadin, 8-80 parts of eugenol, ethyl chinese cymbidium
It is plain 10-80 parts.
4. a kind of pharmaceutical composition for treating atherosclerosis according to claim 1, it is characterised in that：The medicine group
Compound is formulated comprising following raw materials according according to parts by weight：1-50 parts of Rubiadin, 8-50 parts of eugenol, ethyl chinese cymbidium
It is plain 10-50 parts.
5. a kind of pharmaceutical composition for treating atherosclerosis according to claim 1, it is characterised in that：The medicine group
Compound is formulated comprising following raw materials according according to parts by weight：1 part of Rubiadin, 8 parts of eugenol, Ethyl vanillin 15
Part.
6. application of the pharmaceutical composition in the medicine for preparing treatment atherosclerosis as described in claim 1-5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710073121.2A CN107050005A (en) | 2017-01-22 | 2017-01-22 | A kind of pharmaceutical composition for treating atherosclerosis and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710073121.2A CN107050005A (en) | 2017-01-22 | 2017-01-22 | A kind of pharmaceutical composition for treating atherosclerosis and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107050005A true CN107050005A (en) | 2017-08-18 |
Family
ID=59598192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710073121.2A Pending CN107050005A (en) | 2017-01-22 | 2017-01-22 | A kind of pharmaceutical composition for treating atherosclerosis and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107050005A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111534483A (en) * | 2020-05-23 | 2020-08-14 | 南京凡亦达生物科技有限公司 | Application of insulin-like growth factor binding protein 7 activator in chondrogenic differentiation of human umbilical cord mesenchymal stem cells |
| CN115192559A (en) * | 2022-07-20 | 2022-10-18 | 昆明理工大学 | Application of methyl isoalizarin in preparation of medicine for treating intestinal mucosa injury |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105878221A (en) * | 2016-05-30 | 2016-08-24 | 王双喜 | Pharmaceutical composition for preventing atherosclerosis and application thereof |
| CN106074507A (en) * | 2016-05-30 | 2016-11-09 | 新乡医学院 | Pharmaceutical composition that prevention of arterial is atherosis and application thereof |
-
2017
- 2017-01-22 CN CN201710073121.2A patent/CN107050005A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105878221A (en) * | 2016-05-30 | 2016-08-24 | 王双喜 | Pharmaceutical composition for preventing atherosclerosis and application thereof |
| CN106074507A (en) * | 2016-05-30 | 2016-11-09 | 新乡医学院 | Pharmaceutical composition that prevention of arterial is atherosis and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 杨庆明等: "食用香料———香兰素的抗氧化活性研究", 《食品研究与开发》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111534483A (en) * | 2020-05-23 | 2020-08-14 | 南京凡亦达生物科技有限公司 | Application of insulin-like growth factor binding protein 7 activator in chondrogenic differentiation of human umbilical cord mesenchymal stem cells |
| CN111534483B (en) * | 2020-05-23 | 2020-12-18 | 广东壹加再生医学研究院有限公司 | Application of insulin-like growth factor binding protein 7 activator in chondrogenic differentiation of human umbilical cord mesenchymal stem cells |
| CN115192559A (en) * | 2022-07-20 | 2022-10-18 | 昆明理工大学 | Application of methyl isoalizarin in preparation of medicine for treating intestinal mucosa injury |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101903033A (en) | The purposes of the extract of making by Folium Ginkgo | |
| CN107050005A (en) | A kind of pharmaceutical composition for treating atherosclerosis and its application | |
| CN106924226A (en) | A kind of pharmaceutical composition for treating atherosclerosis and application | |
| CN105878221A (en) | Pharmaceutical composition for preventing atherosclerosis and application thereof | |
| CN107158008B (en) | A kind of pharmaceutical composition for treating myocardial infarction | |
| CN106389329B (en) | A kind of Dipyridamole Orally taken emulsion drug delivery system and preparation method thereof | |
| CN108553495A (en) | A kind of antitumor Chinese medicine composition, active ingredient compositions and application thereof and preparation | |
| CN106822067A (en) | Treat the application of the pharmaceutical composition and the pharmaceutical composition of atherosclerosis | |
| CN106668050A (en) | Pharmaceutical composition for treating atherosclerosis and application of pharmaceutical composition | |
| CN106902107A (en) | A kind of pharmaceutical composition for treating atherosclerosis and application | |
| US11369653B2 (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular disease, preparation method therefor and use thereof | |
| CN106074507A (en) | Pharmaceutical composition that prevention of arterial is atherosis and application thereof | |
| CN104546822B (en) | The medical usage of epimedium aglucone | |
| CN106860439A (en) | Treat pharmaceutical composition and the application of atherosclerosis | |
| CN106822096A (en) | Treat the application of the pharmaceutical composition and the pharmaceutical composition of atherosclerosis | |
| CN106668051A (en) | Pharmaceutical composition for treating atherosclerosis and application thereof | |
| CN106822070A (en) | A kind of pharmaceutical composition for treating atherosclerosis and application | |
| CN106176766A (en) | One treats atherosclerotic pharmaceutical composition and application thereof | |
| CN105998045A (en) | Pharmaceutical composition for treating atherosclerosis and application thereof | |
| WO2019100843A1 (en) | Enteromorpha prolifera polysaccharide composite blood lipid-lowering health care product and preparation method therefor | |
| CN108743571A (en) | Prevent, treat the pharmaceutical composition and preparation method thereof of epilepsy | |
| CN108186631A (en) | A kind of pharmaceutical composition and its preparation method and application | |
| CN108434166A (en) | A kind of " Xuesaitong Injection " pharmaceutical composition and preparation method thereof, preparation and application | |
| CN106667977A (en) | Medicinal composition for treating atherosclerosis and application | |
| CN108619137B (en) | Application of carbazole compounds in preparation of medicines for treating metabolic diseases and complications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170818 |